JP6338531B2 - 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ） - Google Patents

膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ） Download PDF

Info

Publication number
JP6338531B2
JP6338531B2 JP2014541761A JP2014541761A JP6338531B2 JP 6338531 B2 JP6338531 B2 JP 6338531B2 JP 2014541761 A JP2014541761 A JP 2014541761A JP 2014541761 A JP2014541761 A JP 2014541761A JP 6338531 B2 JP6338531 B2 JP 6338531B2
Authority
JP
Japan
Prior art keywords
thcv
diabetes
medicament according
insulin
phytocannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014541761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533680A5 (enExample
JP2014533680A (ja
Inventor
カウソーン，マイケル
スコット，コリン
ライト，スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of JP2014533680A publication Critical patent/JP2014533680A/ja
Publication of JP2014533680A5 publication Critical patent/JP2014533680A5/ja
Application granted granted Critical
Publication of JP6338531B2 publication Critical patent/JP6338531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014541761A 2011-11-21 2012-11-20 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ） Active JP6338531B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120066.4 2011-11-21
GB1120066.4A GB2496687A (en) 2011-11-21 2011-11-21 Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
PCT/GB2012/052869 WO2013076471A1 (en) 2011-11-21 2012-11-20 Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells

Publications (3)

Publication Number Publication Date
JP2014533680A JP2014533680A (ja) 2014-12-15
JP2014533680A5 JP2014533680A5 (enExample) 2016-01-14
JP6338531B2 true JP6338531B2 (ja) 2018-06-06

Family

ID=45475480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541761A Active JP6338531B2 (ja) 2011-11-21 2012-11-20 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ）

Country Status (14)

Country Link
US (1) US20160243075A2 (enExample)
EP (2) EP2782568B1 (enExample)
JP (1) JP6338531B2 (enExample)
CN (1) CN103945841A (enExample)
AU (1) AU2013201809B2 (enExample)
BR (1) BR112014012159A2 (enExample)
CA (1) CA2856102A1 (enExample)
DK (1) DK2782568T3 (enExample)
ES (2) ES2560835T3 (enExample)
GB (2) GB2496687A (enExample)
MX (1) MX348564B (enExample)
PL (1) PL2782568T3 (enExample)
PT (1) PT2782568E (enExample)
WO (1) WO2013076471A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
EP3804705B1 (en) * 2018-06-07 2023-09-13 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof
JP2021534141A (ja) * 2018-08-10 2021-12-09 セルビシオ アンダルーサ デ サルー アルコール使用障害の治療剤
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
EP3876704A4 (en) * 2018-11-09 2022-10-26 Agriculture Victoria Services Pty Ltd CANNABIS PLANTS WITH A CANNABINOID PROFILE ENRICHED WITH D-9-TETRAHYDROCANNABINOL, CANNABIGEROL AND TETRAHYDROCANNABIVARIN
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP4188363A4 (en) 2020-07-28 2024-10-16 Wsmef, Llc FULL-SPECTRUM HEMP OIL MICELLE PREPARATIONS FOR THE TREATMENT OF TYPE II DIABETES, REDUCING INFLAMMATION DURING COVID-19 AND IMPROVING SLEEP QUALITY
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CN113135885A (zh) * 2021-04-07 2021-07-20 上海同田生物技术有限公司 一种高速逆流色谱分离纯化四氢次大麻酚的方法
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2024006896A1 (en) * 2022-06-29 2024-01-04 The Regents Of The University Of California Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
KR101368525B1 (ko) * 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen

Also Published As

Publication number Publication date
GB201120066D0 (en) 2012-01-04
BR112014012159A2 (pt) 2017-05-30
US20160243075A2 (en) 2016-08-25
DK2782568T3 (en) 2016-02-08
GB201220874D0 (en) 2013-01-02
EP3028697B1 (en) 2018-12-26
PT2782568E (pt) 2016-02-01
EP3028697A1 (en) 2016-06-08
WO2013076471A1 (en) 2013-05-30
PL2782568T3 (pl) 2016-05-31
AU2013201809B2 (en) 2015-04-23
EP2782568A1 (en) 2014-10-01
ES2714350T3 (es) 2019-05-28
CA2856102A1 (en) 2013-05-30
GB2496687A (en) 2013-05-22
AU2013201809A1 (en) 2013-06-06
US20160015682A2 (en) 2016-01-21
JP2014533680A (ja) 2014-12-15
ES2560835T3 (es) 2016-02-23
CN103945841A (zh) 2014-07-23
MX2014006057A (es) 2014-08-21
GB2496761A (en) 2013-05-22
US20140335208A1 (en) 2014-11-13
EP2782568B1 (en) 2015-10-28
MX348564B (es) 2017-06-20

Similar Documents

Publication Publication Date Title
JP6338531B2 (ja) 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ）
Tak et al. Long-term efficacy and safety of anti-obesity treatment: where do we stand?
Guo et al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial
Yerevanian et al. Metformin: mechanisms in human obesity and weight loss
Wang et al. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis
Thulé Mechanisms of current therapies for diabetes mellitus type 2
Kashani et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression
Wajchenberg β-cell failure in diabetes and preservation by clinical treatment
Del Prato et al. ß‐cell function and anti‐diabetic pharmacotherapy
Vinik et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents
Li et al. Antidiabetic activities of oligosaccharides of Ophiopogonis japonicus in experimental type 2 diabetic rats
JP2018514555A (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
Hagi et al. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: a meta‐analysis of randomized controlled trials
Horton Can newer therapies delay the progression of type 2 diabetes mellitus?
Velíšek et al. Metabolic environment in substantia nigra reticulata is critical for the expression and control of hypoglycemia-induced seizures
Moon et al. Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes
Slouha et al. Anti-diabetics and the prevention of dementia: a systematic review
Seino et al. Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52‐week, randomized, multicenter trial
Agrawal et al. Study of the effect of pantoprazole on glycemic control of type-2 diabetes mellitus in tertiary care center and hospital in North India
Ingle et al. Current trends in pharmacological treatment of type II diabetes mellitus
Mathur et al. A review on current type-2 diabetes mellitus treatment by selected phytoconstituents
Padhye et al. Effect of turmeric on alloxan induced diabetes mellitus in albino rats
US20150037361A1 (en) Compositions and methods to treat the bihormonal disorder in diabetes
Atuahene Effect of Semaglutide on Gonadotropin-Releasing Hormone From GT1-7 Cells
Assad et al. Effect of cabergoline on body weight, glycemic control and insulin resistance in patient with obesity and prediabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180508

R150 Certificate of patent or registration of utility model

Ref document number: 6338531

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250